UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest reported) May 3, 2000
Aquila Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its chapter)
Delaware 000-12081 043307818
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
175 Crossing Boulevard, Framingham, MA 01702
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (508) 628-0100
_____________________________________________________
Item 5. Other Events.
On May 3, 2000, Aquila Biopharmaceuticals, Inc. announced
preliminary results from a licensing trial designed to evaluate
the effectiveness of Quilvax-M(TM) in the management of S.
aureus mastitis in dairy cows. The primary endpoint was a
reduction in the average somatic cell counts over 120 days
following challenge with S. aureus. The preliminary results
show no difference in the primary endpoint measurement
between the control group of animals and those immunized
with Quilvax-M(TM).
Item 7. Financial Statements and Exhibits.
(c) Exhibits. Exhibit 99.1. Aquila Biopharmaceuticals, Inc.
press release dated May 3, 2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
AQUILA BIOPHARMACEUTICALS, INC.
Dated: May 3, 2000
By: /s/ James L. Warren
James L. Warren
Vice President of Finance,
Chief Financial Officer and
Treasurer
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
Contacts: Alison Taunton-Rigby, Ph.D.
Chief Executive Officer
Aquila Biopharmaceuticals, Inc.
508-766-2710
http://www.aquilabio.com
Doug MacDougall or
Karen Lane
Feinstein Kean Healthcare
617-577-8110
AQUILA BIOPHARMACEUTICALS ANNOUNCES
PRELIMINARY RESULTS OF
QUILVAX-M(TM) MASTITIS TRIAL
Framingham, MA, May 3, 2000 - Aquila Biopharmaceuticals,
Inc. (NASD NMS: AQLA) today announced preliminary
results from a licensing trial designed to evaluate the
effectiveness of Quilvax-M(TM) in the management of S.
aureus mastitis in dairy cows. The primary endpoint
was a reduction in the average somatic cell counts
over 120 days following challenge with S. aureus.
The preliminary results show no difference in the primary
endpoint measurement between the control group of animals
and those immunized with Quilvax-M(TM).
"We are disappointed with these results and will
complete a detailed analysis of the data over the next
few weeks in order totally understand the implications",
said Alison Taunton-Rigby,Ph.D., "We remain confident
of the broad utility of our core immune modulation
technologies and adjuvants and we will continue to
advance our other programs including further clinical
testing of Quilimmune-P(TM) (pneumonia) and Quilimmune-M(TM)
(malaria) and pre-clinical work for our CD1 products
for infectious diseases and cancer."
Aquila Biopharmaceuticals, Inc. is a life sciences
company developing a range of proprietary products that
enhance the immune response in animals and humans.
The Company's products are intended for use in treating,
controlling and preventing infectious disease, cancers and
autoimmune disorders. Aquila's QS-21 based products
include Leucoge(R) for protection against feline leukemia
virus (approved for U.S. and European use in 1991);
Quilimmune-M(TM), a human healthcare product for preventing
malaria; Quilimmune-P(TM), for preventing pneumococcal
infections in the elderly and CD1 pre-clinical
programs for infectious diseases and cancer.
The Company also licenses its immune enhancement
technologies, and current partners include SmithKline
Beecham, Elan Corporation, plc, Aventis Pasteur,
Wyeth Lederle, VaxGen, Bristol-Myers Squibb
(Progenics Pharmaceuticals) and Virbac S.A.
Leucogen(R) is a registered mark of Virbac S.A.
Statements in this release that relate to expectations
and objectives of management for future operations of
AquilaBiopharmaceuticals, Inc., or that otherwise relate
to future performance, are forward looking statements.
Actual results may differ from those projected as a result
of product demand, pricing, market acceptance, economic
conditions, intellectual property issues, competitive
products, risks in product and technology development,
and other risks identified in the Company's Securities
and Exchange Commission filings.
For investor inquiries, please call (508) 766-2723.
Press releasesmay be found on the Internet at either
http://www.aquilabio.com,http://www.prnewswire.com
(company news on call), or requestedby fax by
calling (800) 758-5804 X134225.
